Dexcom Positioned to Benefit from Weight Loss Drug Market Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy DXCM?
Source: NASDAQ.COM
- Vast Market Potential: Dexcom's continuous glucose monitoring devices are poised to benefit from the rapid growth of the weight loss drug market, which is expected to attract more diabetes patients to its products, thereby expanding its addressable market and enhancing revenue potential.
- Strong Competitive Advantage: Dexcom has established a robust competitive moat in the medical device sector, with many third-party companies developing devices compatible with its technology, creating a network effect that further enhances its market appeal.
- User Growth Trend: Research indicates that CGM usage grows faster among GLP-1 drug users compared to non-therapy users, suggesting that the proliferation of weight loss drugs will drive demand for Dexcom's products, boosting company performance.
- Underpenetrated Market: In the U.S., over nine million patients eligible for third-party coverage are not using CGM devices, providing Dexcom with opportunities to further expand its market share by entering new territories and launching its over-the-counter product, Stelo.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 62.600
Low
68.00
Averages
82.54
High
100.00
Current: 62.600
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. It enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dexcom Positioned to Benefit from Weight-Loss Drug Market Growth
- Significant Market Potential: According to Dexcom, over nine million patients in the U.S. eligible for third-party coverage are not using CGM devices, indicating a substantial untapped market that could significantly boost the company's revenue in the future.
- Clear Technological Advantage: Dexcom's CGM devices offer real-time monitoring capabilities that improve health outcomes for diabetes patients, and as GLP-1 weight-loss drugs gain popularity, the demand for CGMs is expected to rise, enhancing Dexcom's market position.
- High Competitive Barriers: Dexcom has established a strong competitive advantage, with many third-party companies developing devices compatible with its technology, and as its installed base grows, it attracts more patients into its ecosystem, creating a favorable network effect that further solidifies its market leadership.
- Promising Future Growth: Dexcom has seen substantial financial improvement over the past decade, and with the increasing adoption of CGM technology and expansion into new markets, the company is well-positioned to deliver strong returns over the next decade, capitalizing on vast market opportunities.
See More
Dexcom Positioned to Benefit from Weight Loss Drug Market Growth
- Vast Market Potential: Dexcom's continuous glucose monitoring devices are poised to benefit from the rapid growth of the weight loss drug market, which is expected to attract more diabetes patients to its products, thereby expanding its addressable market and enhancing revenue potential.
- Strong Competitive Advantage: Dexcom has established a robust competitive moat in the medical device sector, with many third-party companies developing devices compatible with its technology, creating a network effect that further enhances its market appeal.
- User Growth Trend: Research indicates that CGM usage grows faster among GLP-1 drug users compared to non-therapy users, suggesting that the proliferation of weight loss drugs will drive demand for Dexcom's products, boosting company performance.
- Underpenetrated Market: In the U.S., over nine million patients eligible for third-party coverage are not using CGM devices, providing Dexcom with opportunities to further expand its market share by entering new territories and launching its over-the-counter product, Stelo.
See More
Abbott vs. Dexcom: The CGM Market Showdown
- Market Leadership: Abbott's FreeStyle Libre has surpassed five million patients in the past three years, becoming the best-selling medical device of all time in dollar sales, showcasing its strong leadership in the CGM market, while Dexcom has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to achieve stable revenue and earnings growth with market-leading devices like MitraClip, while its acquisition in the cancer diagnostics market provides new growth opportunities.
- Competitive Dynamics: Although Dexcom has shown faster revenue growth in the CGM market, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery.
- Investment Choice: For risk-averse investors, Abbott is a better choice due to its stable dividends and market leadership, while Dexcom appeals more to risk-tolerant investors seeking high growth.
See More
Abbott vs. Dexcom: Competition in CGM Market
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
See More
Investment Outlook for Healthcare Tech Companies
- TransMedics Growth Potential: TransMedics Group's Organ Care System (OCS) significantly enhances organ storage and transport efficiency by mimicking human physiology, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Strategy: TransMedics plans to launch the OCS for kidneys to further expand its market, while aggressively expanding in Europe, enhancing its market opportunities, which is expected to drive performance growth over the next decade.
- Dexcom's Market Leadership: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue last year, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing its strong performance in diabetes management.
- Technological Innovation and Market Expansion: Dexcom not only leads the market among diabetes patients but also enters the over-the-counter market with the launch of Stelo, which is expected to attract more potential users and further enhance its long-term growth prospects.
See More
TransMedics and Dexcom's Market Prospects
- TransMedics Innovation: TransMedics Group's Organ Care System (OCS) mimics human physiology to significantly enhance organ storage and transport efficiency, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Opportunities: TransMedics plans to launch the OCS for kidneys to further expand its market coverage, while aggressive expansion in Europe is expected to enhance its market opportunities, driving performance growth over the next decade.
- Dexcom's Sustained Growth: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing strong performance in diabetes management.
- Untapped Market Potential: Despite concerns over the popularity of GLP-1 weight loss drugs, Dexcom's management emphasizes that physicians prescribe CGM devices alongside these therapies, and the vast global market remains largely untapped, promising long-term returns for the company.
See More
Dexcom Positioned to Benefit from Weight-Loss Drug Market Growth
- Significant Market Potential: According to Dexcom, over nine million patients in the U.S. eligible for third-party coverage are not using CGM devices, indicating a substantial untapped market that could significantly boost the company's revenue in the future.
- Clear Technological Advantage: Dexcom's CGM devices offer real-time monitoring capabilities that improve health outcomes for diabetes patients, and as GLP-1 weight-loss drugs gain popularity, the demand for CGMs is expected to rise, enhancing Dexcom's market position.
- High Competitive Barriers: Dexcom has established a strong competitive advantage, with many third-party companies developing devices compatible with its technology, and as its installed base grows, it attracts more patients into its ecosystem, creating a favorable network effect that further solidifies its market leadership.
- Promising Future Growth: Dexcom has seen substantial financial improvement over the past decade, and with the increasing adoption of CGM technology and expansion into new markets, the company is well-positioned to deliver strong returns over the next decade, capitalizing on vast market opportunities.
See More
Dexcom Positioned to Benefit from Weight Loss Drug Market Growth
- Vast Market Potential: Dexcom's continuous glucose monitoring devices are poised to benefit from the rapid growth of the weight loss drug market, which is expected to attract more diabetes patients to its products, thereby expanding its addressable market and enhancing revenue potential.
- Strong Competitive Advantage: Dexcom has established a robust competitive moat in the medical device sector, with many third-party companies developing devices compatible with its technology, creating a network effect that further enhances its market appeal.
- User Growth Trend: Research indicates that CGM usage grows faster among GLP-1 drug users compared to non-therapy users, suggesting that the proliferation of weight loss drugs will drive demand for Dexcom's products, boosting company performance.
- Underpenetrated Market: In the U.S., over nine million patients eligible for third-party coverage are not using CGM devices, providing Dexcom with opportunities to further expand its market share by entering new territories and launching its over-the-counter product, Stelo.
See More
Abbott vs. Dexcom: The CGM Market Showdown
- Market Leadership: Abbott's FreeStyle Libre has surpassed five million patients in the past three years, becoming the best-selling medical device of all time in dollar sales, showcasing its strong leadership in the CGM market, while Dexcom has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to achieve stable revenue and earnings growth with market-leading devices like MitraClip, while its acquisition in the cancer diagnostics market provides new growth opportunities.
- Competitive Dynamics: Although Dexcom has shown faster revenue growth in the CGM market, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery.
- Investment Choice: For risk-averse investors, Abbott is a better choice due to its stable dividends and market leadership, while Dexcom appeals more to risk-tolerant investors seeking high growth.
See More
Abbott vs. Dexcom: Competition in CGM Market
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
See More
Investment Outlook for Healthcare Tech Companies
- TransMedics Growth Potential: TransMedics Group's Organ Care System (OCS) significantly enhances organ storage and transport efficiency by mimicking human physiology, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Strategy: TransMedics plans to launch the OCS for kidneys to further expand its market, while aggressively expanding in Europe, enhancing its market opportunities, which is expected to drive performance growth over the next decade.
- Dexcom's Market Leadership: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue last year, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing its strong performance in diabetes management.
- Technological Innovation and Market Expansion: Dexcom not only leads the market among diabetes patients but also enters the over-the-counter market with the launch of Stelo, which is expected to attract more potential users and further enhance its long-term growth prospects.
See More
TransMedics and Dexcom's Market Prospects
- TransMedics Innovation: TransMedics Group's Organ Care System (OCS) mimics human physiology to significantly enhance organ storage and transport efficiency, achieving $605.5 million in revenue in 2025, a 37% increase, indicating strong growth potential in the organ transplant market.
- Market Expansion Opportunities: TransMedics plans to launch the OCS for kidneys to further expand its market coverage, while aggressive expansion in Europe is expected to enhance its market opportunities, driving performance growth over the next decade.
- Dexcom's Sustained Growth: Dexcom's continuous glucose monitoring devices generated $4.7 billion in revenue in 2025, a 16% increase, with earnings per share rising from $1.42 to $2.09, showcasing strong performance in diabetes management.
- Untapped Market Potential: Despite concerns over the popularity of GLP-1 weight loss drugs, Dexcom's management emphasizes that physicians prescribe CGM devices alongside these therapies, and the vast global market remains largely untapped, promising long-term returns for the company.
See More
